Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
GlucoTrack ( (GCTK) ) has provided an announcement.
On February 26, 2025, Glucotrack, Inc. announced the appointment of Dr. Guillermo Umpierrez, a leading diabetes researcher and clinician, to its Medical Advisory Board. This strategic move is expected to enhance the company’s development of its innovative Continuous Blood Glucose Monitoring (CBGM) technology, which aims to improve diabetes care by offering a less intrusive and more accurate monitoring solution. Dr. Umpierrez’s extensive experience in diabetes research and care will be instrumental as Glucotrack progresses into human clinical trials, potentially strengthening its position in the diabetes care industry and offering significant advancements for stakeholders.
More about GlucoTrack
Glucotrack, Inc. is a medical device company that focuses on the design, development, and commercialization of novel technologies for people with diabetes. The company is currently developing a long-term implantable continuous blood glucose monitoring system.
YTD Price Performance: -95.50%
Average Trading Volume: 3,603,209
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $3.5M
See more insights into GCTK stock on TipRanks’ Stock Analysis page.